Based on strong preclinical data on HMPL-A251 in HER2-positive tumor cell lines, the firm wants to take the therapy into clinical trials by year end.
TipRanks on MSN
Oncopeptides’ NK Cell Engager Study to be Presented at ASH
The latest update is out from Oncopeptides AB ( (SE:ONCO) ).
Based on its Q3 performance, the firm raised its full-year sales and EPS guidance and is now expecting sales to be between ...
4don MSN
Molecular profiling of renal medullary carcinoma identifies TROP2 as a promising therapeutic target
Researchers at The University of Texas MD Anderson Cancer Center, in collaboration with BostonGene, conducted the largest and ...
Advancing AT-01, a first-in-class ADC programme, with strong preclinical validation towards IND/CTA-enabling studies, expected to begin in the first half of 2026 Leadership and Board strengthened with ...
CURE spoke with Dr. Surbhi Sidana about the recently approved antibody-drug conjugate Blenrep for multiple myeloma.
Created and written by John Wick and Nobody writer Derek Kolstad, Splinter Cell: Deathwatch is the first animated series to spin out of Splinter Cell, the 25-year-old Ubisoft video game franchise, ...
GameSpot may get a commission from retail offers. This month, Netflix debuted the new animated series, Splinter Cell: Deathwatch, which brings back Tom Clancy's Sam Fisher, the lead character of ...
GameSpot may get a commission from retail offers. There’s a scene in Splinter Cell: Deathwatch--Netflix's animated adaptation of Ubisoft's stealth game series--where Sam Fisher casually walks in front ...
In a bulletin on Friday, GM announced that it will end its HYDROTEC brand's work on hydrogen fuel cell development. Instead, GM will focus its R&D efforts on batteries, charging technologies and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback